- Home
- NIU vs TVRD Comparison
NIU vs TVRD Comparison
Compare NIU & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIU
- TVRD
- Stock Information
- Founded
- NIU 2014
- TVRD 2017
- Country
- NIU China
- TVRD United States
- Employees
- NIU N/A
- TVRD N/A
- Industry
- NIU Auto Manufacturing
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- NIU Consumer Discretionary
- TVRD Health Care
- Exchange
- NIU Nasdaq
- TVRD Nasdaq
- Market Cap
- NIU 275.6M
- TVRD 246.5M
- IPO Year
- NIU 2018
- TVRD N/A
- Fundamental
- Price
- NIU $4.34
- TVRD $31.11
- Analyst Decision
- NIU
- TVRD Strong Buy
- Analyst Count
- NIU 0
- TVRD 5
- Target Price
- NIU N/A
- TVRD $59.20
- AVG Volume (30 Days)
- NIU 967.3K
- TVRD 20.2K
- Earning Date
- NIU 08-11-2025
- TVRD 08-14-2025
- Dividend Yield
- NIU N/A
- TVRD N/A
- EPS Growth
- NIU N/A
- TVRD N/A
- EPS
- NIU N/A
- TVRD N/A
- Revenue
- NIU $527,760,629.00
- TVRD N/A
- Revenue This Year
- NIU $41.32
- TVRD N/A
- Revenue Next Year
- NIU $24.38
- TVRD N/A
- P/E Ratio
- NIU N/A
- TVRD N/A
- Revenue Growth
- NIU 32.62
- TVRD N/A
- 52 Week Low
- NIU $1.66
- TVRD $8.13
- 52 Week High
- NIU $5.37
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- NIU 51.37
- TVRD 66.56
- Support Level
- NIU $4.20
- TVRD $28.20
- Resistance Level
- NIU $4.96
- TVRD $31.54
- Average True Range (ATR)
- NIU 0.24
- TVRD 1.81
- MACD
- NIU -0.07
- TVRD 0.35
- Stochastic Oscillator
- NIU 15.91
- TVRD 90.48
About NIU Niu Technologies
Niu Technologies designs, manufactures and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycle, mopeds and bicycle series, including the NQi, MQi, UQi, F series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.